NCT02626884已完成2 期
Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 14
- 试验地点
- 1
- 主要终点
- Response Rate
研究概览
简要总结
The purpose of this trial is to determine
- Disease stabilization/response rate after six 21-day cycles of ibrutinib
- Remission status after six, twelve and 20 21-day cycles of ibrutinib
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 99 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- 未提供
排除标准
- 未提供
研究组 & 干预措施
Ibrutinib
Experimental
All patient receive ibrutinib at a dose of 560 mg/d for up to 20 21-day cycles
干预措施: Ibrutinib (Drug)
结局指标
主要结局
Response Rate
时间窗: after 6 cycles (each cycle is 21 days) of Ibrutinib
次要结局
- Remission status(Remission status after six, twelve and 20 21-day cycles of ibrutinib)
研究者
Prof. Dr. Andreas Engert
Prof.
University of Cologne
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Study of Ibrutinib and Rituximab in Treatment Naïve Follicular LymphomaFollicular LymphomaNCT02947347Pharmacyclics LLC.445
已完成
不适用
A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World SettingLeukemia, Lymphocytic, Chronic, B-CellNCT03720561Janssen-Cilag S.p.A.312
撤回
2 期
IPI-145 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)LeukemiaNCT02028039M.D. Anderson Cancer Center
招募中
2 期
Fixed-duration Therapy With Ibrutinib and Obinutuzumab (GA-101) in Treatment-naïve Patients With CLLChronic Lymphocytic LeukemiaNCT04908228Paolo Ghia53
尚未招募
2 期
Blinatumomab Prevents Recurrence of R/R ALL After Allo-HSCTLeukemia, LymphoidNCT06075238Sichuan University68